Molecular Quality Control Market Size to Exceed USD 365.9 Mn by 2032

The Molecular Quality Control Market, estimated at USD 223.3 Mn in 2025, is expected to exhibit a CAGR of 7.3% and reach USD 365.9 Mn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Market Dynamics

Increasing prevalence of chronic diseases due to changing lifestyle habits and growth of geriatric population can boost demand for molecular quality controls. In October 2025, according to the United Nations, the global population aged 60 years and older can increase from 962 million in 2025 to 2.1 billion by 2050. Chronic diseases such as cancer, diabetes, and heart disease tend to more commonly occur in the aged population. This rising geriatric population base will generate higher demand for disease diagnosis and management. Stringent regulations for quality control and standardization of results across diagnostic laboratories boosts adoption of molecular quality controls. Government bodies worldwide like the U.S. Food and Drug Administration (FDA) are focusing on improving the quality of diagnostic processes by implementing various standards and procedures. The use of quality control samples helps labs authenticate their testing procedures and identify any errors. This fosters quality assurance and improves accuracy.

Advancement in Molecular Diagnostic Test Techniques Drives Market Growth

Advancement and growing adoption of PCR, NGS, microarray and other molecular diagnostic test techniques can drive the growth of global molecular quality control market. Molecular diagnostic tests offer accuracy, faster turnaround time, and the ability to detect diseases at an early stage compared to conventional diagnostic methods. Growing demand for early and accurate disease diagnosis encourages pharmaceutical and biotechnology companies to invest heavily in developing innovative molecular diagnostic test solutions. This is subsequently increasing the need for rigorous quality control testing of these molecular diagnostic products to ensure reliability and reproducibility of test results. Various regulatory agencies also mandate strict quality control protocols for in-vitro diagnostic products, which boosts demand for molecular quality control samples and reagents.

Growing Focus on Personalized Medicine Drives Market Growth

Growing focus of pharmaceutical companies and researchers on developing personalized medicines can also drive the molecular quality control market growth. Personalized medicine involves tailoring medical treatment according to an individual's genetic profile, and is largely dependent on molecular diagnostic tools. Increasing development and commercialization of companion diagnostics, which are used to identify appropriate treatment options for a specific patient, boosts the need for robust quality control systems. Molecular quality control products play a vital role in validating companion diagnostic assays and ensuring reproducible and accurate results. This growing importance of molecular diagnostics in personalized healthcare boosts demand in the global molecular quality control market.

High Cost of Molecular Diagnostic Tests Acts as Market Restraint

High cost associated with molecular diagnostic tests compared to traditional diagnostic methods can hamper the growth of molecular quality control market. Setting up molecular diagnostic labs and establishing robust quality control protocols requires huge capital investments. Overall operational costs of molecular diagnostic testing, including costs related to sample collection, extraction, reagents, and dedicated equipment are significantly higher. This makes molecular diagnostic tests expensive and unaffordable for many individuals, particularly in developing countries. However, with advancements in microfluidics and lab-on-a-chip technologies, the costs of molecular diagnostic tools and quality control products is expected to reduce in the future, negating this restraint.

Lack of Skilled Professionals Hinders Market Growth

Lack of availability of highly trained healthcare professionals for performing complex molecular diagnostic tests and establishing quality control protocols poses challenges to molecular quality control market growth. Conducting molecular diagnostic tests requires specialized technical skills and knowledge that are currently limited to scientists and technicians in core diagnostic laboratories. The dearth of professionals skilled in molecular diagnostic techniques makes it difficult to implement gold-standard quality control programs. Setting up of dedicated training and certification programs to bridge this skill gap can help alleviate this restraint. Ongoing research to develop easy-to-use, automated molecular diagnostic platforms can reduce dependence on specialized skills.

Growing Molecular Diagnostic Markets in Emerging Countries Present Lucrative Opportunities

Rapidly expanding molecular diagnostic markets in emerging countries such as China, India, Brazil, Mexico and countries in the Middle East present significant growth opportunities for molecular quality control market players. Factors such as improving healthcare infrastructure, rising awareness, growing disposable incomes, and increasing government investments in developing advanced diagnostics boosts demand for in-vitro diagnostic products in developing regions. Stringent regulatory frameworks are being established in countries like the U.S to ensure reliability and accuracy of diagnostic testing. This will likely propel the need for robust quality control systems, thus, driving the molecular quality control market growth. Players could leverage the absence of strong competition and tap into the immense market potential in developing markets.

 Increasing Adoption of POC Molecular Diagnostics Spells Opportunities

Rising popularity of point-of-care (POC) molecular diagnostic tests provides opportunities for molecular quality control product manufacturers. POC tests help deliver faster results outside conventional laboratory settings, enabling timely clinical decisions. Various start-ups are actively developing portable, easy-to-use, rapid POC molecular diagnostic devices for diseases like influenza, HIV, and cancer. Growing adoption of such POC tests will necessitate quality control protocols to validate near-patient testing outside strict lab environments. Firms could introduce molecular quality controls in innovative formats suitable for field or home-based POC testing to capitalize on this opportunity. Customizable quality control packs and cloud-based data management services would address the needs of POC molecular testing.

Link: https://www.coherentmarketinsights.com/market-insight/molecular-quality-control-market-2674

Key Developments

• On November 6, 2025, Microbiologics, a global leader in infectious disease reference materials and contract research, announced the acquisition of SensID, a Germany-based company that specializes in molecular diagnostics for oncology and precision medicine. This acquisition marks Microbiologics' first international expansion, enhancing its oncology portfolio while continuing to lead in infectious disease diagnostics.
• On June 11, 2025, Bio-Rad Laboratories, a life science company, expanded its molecular quality control offerings by launching the Exact Diagnostics GBS Positive and Negative Run Controls. These ready-to-use controls are designed to assess assay performance, operator proficiency, and workflow accuracy for Group B Streptococcus (GBS) molecular assays.
• In February 2025, ZeptoMetrix, an Antylia Scientific company, launched the SARS-CoV-2 Omicron Control, further, expanding its infectious disease quality control portfolio. The product, available for pre-order, facilitates reliable testing by addressing mutations in the SARS-CoV-2 virus.
• On November 18, 2025, Roche, a pharmaceutical company, introduced the cobas 5800 System, a compact molecular laboratory instrument, in CE-mark-accepting countries. Designed to meet growing testing demands, the system provides timely and reliable results, supports diverse testing needs, and helps laboratories manage increasing workloads and reimbursement complexities.

Key Players

Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Microbiologics, Inc., ZeptoMetrix Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Quidel Corporation, Qnostics, Maine Molecular Quality Controls, Inc., Danaher Corporation, Helena Biosciences Europe, SERO AS, Technopath Clinical Diagnostics, Randox Laboratories Ltd., and Hologic, Inc.